Reviewing Aevi Genomic Medicine (GNMX) and ContraFect Corporation (CFRX)
ContraFect Corporation (NASDAQ: CFRX) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitabiliy and analyst recommendations.
This table compares ContraFect Corporation and Aevi Genomic Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-108.08%||-95.41%|
This is a breakdown of current ratings and target prices for ContraFect Corporation and Aevi Genomic Medicine, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||1||0||2.50|
ContraFect Corporation currently has a consensus price target of $5.00, indicating a potential upside of 300.00%. Aevi Genomic Medicine has a consensus price target of $5.25, indicating a potential upside of 341.18%. Given Aevi Genomic Medicine’s higher probable upside, analysts plainly believe Aevi Genomic Medicine is more favorable than ContraFect Corporation.
Institutional & Insider Ownership
25.3% of ContraFect Corporation shares are owned by institutional investors. Comparatively, 28.0% of Aevi Genomic Medicine shares are owned by institutional investors. 9.3% of ContraFect Corporation shares are owned by insiders. Comparatively, 24.8% of Aevi Genomic Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ContraFect Corporation and Aevi Genomic Medicine’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|ContraFect Corporation||N/A||N/A||-$32.36 million||($0.77)||-1.62|
|Aevi Genomic Medicine||N/A||N/A||-$41.42 million||($1.15)||-1.03|
ContraFect Corporation is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ContraFect Corporation has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Aevi Genomic Medicine beats ContraFect Corporation on 6 of the 10 factors compared between the two stocks.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.